Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 12/20 | 0.42 |
| ▸ | ITGAV | P06756 | 12/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 12/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 6/20 | 0.39 |
| ▸ | ITGB5 | P18084 | 6/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20574506 | 0.94 | ITGB3 (0.41) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL20575157 | 0.93 | ITGB3 (0.41) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL20574531 | 0.92 | ITGB3 (0.42) | ITGB3ITGAVITGA2BADRB2ADRB1 | |
| SCHEMBL20575094 | 0.89 | ITGB3 (0.42) | ITGB3ITGAVITGA2BADRB2ADRB1 | |
| SCHEMBL20575045 | 0.88 | ITGB3 (0.40) | ITGB3ITGAVITGA2BADRB2ADRB1 | |
| SCHEMBL2841957 | 0.87 | ITGB3 (0.55) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL20575184 | 0.86 | ITGB3 (0.39) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL2835455 | 0.85 | ITGB3 (0.49) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL20575083 | 0.84 | MEN1 (0.36) | ITGB3ITGAVITGA2B | |
| SCHEMBL20575617 | 0.84 | ITGB3 (0.42) | ITGB3ITGAVITGA2BITGB1ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180344803-A1 | Methods and Compositions For the Treatment of Proteinuric Diseases | THE GENERAL HOSPITAL CORPORATION | 2018-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180344803-A1 | Methods and Compositions For the Treatment of Proteinuric Diseases | ITGB3, PLAUR, PROC | ITGB3 1/4885ITGAV 16/4885ITGA2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.